NLTX Stock Overview
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology.
Neoleukin Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.67|
|52 Week High||US$8.01|
|52 Week Low||US$0.62|
|1 Month Change||-33.91%|
|3 Month Change||-33.91%|
|1 Year Change||-90.27%|
|3 Year Change||-76.66%|
|5 Year Change||-95.23%|
|Change since IPO||-94.41%|
Recent News & Updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|NLTX||US Biotechs||US Market|
Return vs Industry: NLTX underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: NLTX underperformed the US Market which returned -23.2% over the past year.
|NLTX Average Weekly Movement||11.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: NLTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NLTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company’s lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019.
Neoleukin Therapeutics, Inc. Fundamentals Summary
|NLTX fundamental statistics|
Is NLTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NLTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.45|
|Net Profit Margin||0.00%|
How did NLTX perform over the long term?See historical performance and comparison